This interpretation agreed with the model that hepatic NPC1L1 should be a cholesterol re-absorber from bile and the prevention of hepatic NPC1L1-mediated steatosis formation by the administration of ezetimibe, an NPC1L1 inhibitor (Additional file 1: Figure S2). This evidence concerns the gene NPC1L1 and steatosis.